

Synthesis of Tetracyclic Oxindoles from Isatin Containing Baylis-Hillman Adducts via Pd-Catalyzed Aryl-Aryl Coupling and Reduction with NaBH₄

Hyun Seung Lee, Ko Hoon Kim, Yu Mi Kim, and Jae Nyong Kim*

Department of Chemistry and Institute of Basic Science, Chonnam National University, Gwangju 500-757, Korea

*E-mail: kimjn@chonnam.ac.kr

Received March 18, 2010, Accepted April 11, 2010

Key Words: Oxindoles, Isatin, Baylis-Hillman adducts, Palladium, NaBH₄


Numerous poly-fused heterocyclic compounds having a medium-sized ring were known to possess many interesting biological activities.^{1,2} As an example, various indole moiety-containing tetracyclic compounds showed hepatitis C virus (HCV) NS5B polymerase inhibitory activity.² Palladium-catalyzed direct aryl-aryl bond-forming protocols have been used extensively for the synthesis of poly-fused heterocyclic compounds.^{3,4} Recently we reported the synthesis of tetracyclic compounds having a heterocyclic moiety such as indole, imidazole, benzimidazole and isatin, starting from the Baylis-Hillman adduct.^{4a,b}

Many 3-hydroxyoxindole moiety-containing compounds showed interesting biological activities,⁵ thus development of a synthetic methodology and derivatization of 3-hydroxyoxindoles is very important. In these contexts, we decided to examine the synthesis of tetracyclic hydroxyoxindole derivatives. Our synthetic strategy of a tetracyclic 3-hydroxyoxindoles **5a-d** is depicted in Scheme 1. The required starting materials **4a-d** were prepared in 50 - 65% yields from **3a-d**, prepared by the reaction of Baylis-Hillman acetate **1** and isatin derivatives **2a-d**, under the influence of Pd(OAc)₂/TBAB (tetrabutylammonium bromide)/K₂CO₃ in DMF (100 °C, 15 min), by following the previous method.^{4b}


Initially we ran the reduction of **4a** with NaBH₄ at room temperature; however, TLC showed the formation of many spots. Literature survey stated that the reduction of isatin derivatives with NaBH₄ was somewhat complex.⁶ Based on the reported method,^{6a} in which described the reduction of isatin at high temperature in short time produced the best result, we carried out the reduction of **4a** with NaBH₄ (2.0 equiv) in MeOH at refluxing temperature (5 min) and obtained 3-hydroxyoxindole derivative **5a** in a reasonable yield (69%). However, the yield

was quite dependent on the reaction time. Depending on time progress formations of other compounds were observed on TLC. Thus the reaction mixture has to be quenched instantaneously after 4 - 5 min by pouring into cold water, and the crude product has to be separated with organic solvent. Otherwise the yield of product was dramatically decreased. By using this method we carried out the reductions of **4b-d** at refluxing temperature in short time, and obtained **5b-d** in moderate yields (52 - 72%), as shown in Scheme 1.


In order to understand the unusual observations during the reductions of **4a-d**, we examined the reduction of **4c** at low temperature with NaBH₄ (2.0 equiv), as shown in Scheme 2. When we ran the reaction of **4c** at 0 °C, compound **5c** was observed as the major component in short time (5 min). However,



Scheme 2



Scheme 1



Scheme 3

compound **5c** was gradually converted to **6c** via the conjugate addition of a hydride,⁷ and **6c** was the major component after around 30 min. Unexpectedly, however, compound **6c** was again changed to another compound **7c** slowly. Thus we carried out the reduction of **4c** three times in order to identify the structures of these compounds, **6c** and **7c**. First run was carried out at 0 °C and the reaction mixture was quenched after 5 min, and compound **5c** was isolated in 60%. When we ran the reaction at 0 °C for 30 min, compound **6c** was isolated in 51%. Finally, the reaction of **4c** at room temperature for 2 h afforded **7c** in 58%. A facile conjugate reduction⁷ of **5c** to **6c** and unusual oxidation of **6c** to **7c** in the presence of a reducing agent NaBH₄ were interesting.

The unusual oxidation was observed with 3-hydroxyoxindole **8**, as shown in Scheme 3. Complete oxidation of **8** to **9** was observed in MeOH at room temperature within 30 min in the presence of NaBH₄. Without NaBH₄, compound **8** was stable in MeOH and we could not observe the formation of **9** up to 24 h. The reaction of **8** in AcOH (100 °C, 3 h) produced **9** quantitatively.^{8c} In addition, treatment of **8** with K₂CO₃ or NaOMe in MeOH readily produced **9** within 30 min at room temperature almost quantitatively. From the results we tentatively assume that aerobic oxidation of **8** can occur easily in the presence of an acid or base catalyst via the corresponding enol or enolate intermediates.⁸ Some basic species such as [BH₃(OMe)]⁻ anion,⁹ produced by the decomposition of NaBH₄ in MeOH, might be the reason for the facile air oxidation of compound **8** (Scheme 3) and compound **6c** (Scheme 2).

In summary, tetracyclic hydroxyoxindole derivatives were synthesized via a Pd-catalyzed aryl-aryl coupling and the following reduction with NaBH₄ from isatin moiety-containing Baylis-Hillman adducts. The screening of biological activities of prepared compounds is underway and will be reported in due course.

Experimental Section

Typical experimental procedure of 5a. The syntheses of **4a** and **4b** were already reported by us,^{4b} and the starting materials **4c** (61%) and **4d** (65%) were prepared similarly.^{4b} A stirred solution of **4a** (160 mg, 0.5 mmol) and NaBH₄ (39 mg, 1.0 mmol) in MeOH (3 mL) was heated to reflux for 5 min. The reaction mixture was poured into cold water. After the usual aqueous extractive workup with CH₂Cl₂ and column chromatographic purification process (hexanes/EtOAc, 1:4) compound **5a** was obtained as a pale yellow solid, 111 mg (69%). The selected

spectroscopic data of unknown compounds **4c**, **4d**, **5a-d**, **6c**, and **7c** are as follows.

Compound 4c: 61%; orange solid, mp 203 - 205 °C; IR (KBr) 1741, 1719, 1275, 1260 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 2.33 (s, 3H), 3.80 (s, 3H), 3.90 (d, *J* = 13.8 Hz, 1H), 5.32 (d, *J* = 13.8 Hz, 1H), 7.11 (d, *J* = 1.8 Hz, 1H), 7.25 (d, *J* = 7.5 Hz, 1H), 7.32 (d, *J* = 7.5 Hz, 1H), 7.44-7.55 (m, 3H), 8.20 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 20.43, 37.82, 52.52, 118.98, 125.46, 126.70, 128.17, 128.35, 129.22, 130.02, 132.49, 134.03, 134.49, 136.61, 143.48, 144.19, 146.15, 157.82, 165.82, 184.13; ESIMS *m/z* 356 (M⁺+Na). Anal. Calcd For C₂₀H₁₅NO₄: C, 72.06; H, 4.54; N, 4.20. Found: C, 72.37; H, 4.81; N, 4.08.

Compound 4d: 65%; orange solid, mp 151 - 153 °C (decomp); IR (KBr) 1738, 1720, 1488, 1294 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 3.79 (s, 3H), 3.80 (s, 3H), 3.87 (d, *J* = 13.8 Hz, 1H), 5.31 (d, *J* = 13.8 Hz, 1H), 6.86 (d, *J* = 2.4 Hz, 1H), 7.17 (d, *J* = 2.4 Hz, 1H), 7.26 (d, *J* = 7.5 Hz, 1H), 7.34 (d, *J* = 7.5 Hz, 1H), 7.45-7.55 (m, 2H), 8.20 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 37.79, 52.48, 55.94, 109.31, 119.42, 128.13, 128.17, 128.52, 129.03, 129.16, 130.01, 132.40, 134.44, 136.17, 140.24, 146.03, 156.41, 157.83, 165.74, 184.20; ESIMS *m/z* 372 (M⁺+Na).

Compound 5a (1:1 mixture of rotamers): 69%; pale yellow solid, mp 134 - 136 °C; IR (KBr) 3324, 1717, 1700, 1290 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 3.78 (s, 3H*0.5), 3.79 (s, 3H*0.5), 3.88 (d, *J* = 13.8 Hz, 1H*0.5), 3.92 (d, *J* = 13.5 Hz, 1H*0.5), 3.96 (br s, 1H*0.5), 4.07 (br s, 1H*0.5), 5.05 (s, 1H*0.5), 5.20 (s, 1H*0.5), 5.25 (d, *J* = 13.8 Hz, 1H*0.5), 5.31 (d, *J* = 13.5 Hz, 1H*0.5), 7.02 (d, *J* = 7.2 Hz, 2H*0.5), 7.13 (dd, *J* = 7.5 and 7.2 Hz, 2H*0.5), 7.21 (d, *J* = 7.5 Hz, 2H*0.5), 7.28 (d, *J* = 7.5 Hz, 2H*0.5), 7.36-7.51 (m, 6H*0.5), 8.14 (s, 2H*0.5); ¹³C NMR (CDCl₃, 75 MHz) δ 37.49, 37.81, 52.36, 52.38, 69.73, 70.28, 123.41, 123.62, 124.74, 124.86, 125.23, 125.51, 127.31, 127.61, 127.66, 127.74, 127.89, 128.00, 129.47, 129.58, 129.80, 129.89, 132.88, 133.18, 134.56, 134.65, 134.78, 134.90, 137.88, 137.95, 138.99, 139.60, 145.75, 146.10, 166.10, 166.15, 175.22, 175.93; ESIMS *m/z* 344 (M⁺+Na). Anal. Calcd For C₁₉H₁₅NO₄: C, 71.02; H, 4.71; N, 4.36. Found: C, 71.35; H, 4.64; N, 4.11.

Compound 5b (1:1 mixture of rotamers): 52%; pale yellow solid; IR (KBr) 3412, 1731, 1459, 1436, 1291 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 3.78 (s, 3H*0.5), 3.79 (s, 3H*0.5), 3.85 (d, *J* = 13.5 Hz, 1H*0.5), 3.89 (d, *J* = 13.5 Hz, 1H*0.5), 4.53 (br s, 2H*0.5), 5.06 (s, 1H*0.5), 5.21 (s, 1H*0.5), 5.22 (d, *J* = 13.5 Hz, 1H*0.5), 5.29 (d, *J* = 13.5 Hz, 1H*0.5), 7.01-7.03 (m, 2H*0.5), 7.20-7.30 (m, 4H*0.5), 7.37-7.52 (m, 6H*0.5), 8.12 (s, 2H*0.5); ¹³C NMR (CDCl₃, 75 MHz) δ 37.55, 37.83, 52.41, 52.42, 69.55, 70.06, 125.04, 125.23, 126.43, 126.65, 128.02,

128.13 (2C), 28.20, 128.83, 129.00, 129.32, 129.34, 129.64, 129.69, 129.95, 130.05, 132.66, 132.95, 133.89, 133.93, 134.48, 134.57, 136.51, 136.62, 137.45, 138.08, 145.49, 145.91, 165.95, 165.97, 175.44, 176.10; ESIMS m/z 378 (M^+ +Na), 380 (M^+ +2+Na).

Compound 5c (1:1 mixture of rotamers): 72%; pale yellow solid, mp 182 - 184 °C; IR (KBr) 3400, 1724, 1275 cm^{-1} ; 1H NMR ($CDCl_3$, 300 MHz) δ 2.31 (s, 3H*0.5), 2.32 (s, 3H*0.5), 3.77 (s, 3H*0.5), 3.78 (s, 3H*0.5), 3.85 (d, J = 13.8 Hz, 1H*0.5), 3.89 (d, J = 13.8 Hz, 1H*0.5), 4.54 (br s, 1H*0.5), 4.69 (br s, 1H*0.5), 5.05 (s, 1H*0.5), 5.20 (s, 1H*0.5), 5.23 (d, J = 13.8 Hz, 1H*0.5), 5.29 (d, J = 13.8 Hz, 1H*0.5), 6.81-6.83 (m, 2H*0.5), 7.17-7.21 (m, 2H*0.5), 7.27-7.29 (m, 4H*0.5), 7.37-7.49 (m, 4H*0.5), 8.12 (s, 2H*0.5); ^{13}C NMR ($CDCl_3$, 75 MHz) δ 20.69, 20.72, 37.43, 37.72, 52.27, 52.29, 69.74, 70.28, 124.84, 125.06, 125.58, 125.78, 127.48, 127.56, 127.75, 127.79, 127.89, 127.99, 129.45, 129.62, 129.71, 129.77, 132.72, 132.98, 133.01, 133.24, 134.47, 134.57, 134.77, 134.80, 136.32, 136.93, 137.94, 138.01, 145.62, 145.98, 166.08, 166.11, 175.79, 176.47; ESIMS m/z 358 (M^+ +Na). Anal. Calcd For $C_{20}H_{17}NO_4$: C, 71.63; H, 5.11; N, 4.18. Found: C, 71.57; H, 5.42; N, 4.34.

Compound 5d (1:1 mixture of rotamers): 55%; pale yellow solid; IR (KBr) 3368, 1724, 1478 cm^{-1} ; 1H NMR ($CDCl_3$, 300 MHz) δ 3.72-3.89 (m, 2H*0.5), 3.77 (s, 3H*0.5), 3.78 (s, 3H*0.5), 3.79 (s, 3H*0.5), 3.80 (s, 3H*0.5), 4.46 (br s, 1H*0.5), 4.61 (br s, 1H*0.5), 5.05 (s, 1H*0.5), 5.20 (s, 1H*0.5), 5.22 (d, J = 14.1 Hz, 1H*0.5), 5.28 (d, J = 13.8 Hz, 1H*0.5), 6.55 (s, 1H*0.5), 6.56 (s, 1H*0.5), 7.08-7.51 (m, 10H*0.5), 8.13 (s, 2H*0.5); ^{13}C NMR ($CDCl_3$, 75 MHz) δ 37.49, 37.78, 52.33, 52.35, 55.78, 55.79, 70.07, 70.58, 111.53, 111.82, 119.24, 119.35, 125.91, 126.13, 127.71, 127.79, 127.87, 127.98, 128.97, 129.23, 129.50, 129.69, 129.77, 129.83, 132.04, 132.61, 132.67, 132.97, 134.51, 134.60, 137.63, 137.73, 145.51, 145.89, 156.21, 156.39, 166.08, 166.11, 175.58, 176.27; ESIMS m/z 374 (M^+ +Na).

Compound 6c (1:1 mixture of rotamers and the relative stereochemistry between OH and COOMe was not confirmed): 51%; pale yellow solid, mp 120 - 122 °C; IR (KBr) 3400, 1732, 1489, 1275, 764, 751 cm^{-1} ; 1H NMR ($CDCl_3$, 300 MHz) δ 2.36 (s, 3H*0.5), 2.37 (s, 3H*0.5), 2.96-3.37 (m, 8H*0.5), 3.73 (s, 3H*0.5), 3.74 (s, 3H*0.5), 3.77 (d, J = 4.5 Hz, 1H*0.5), 3.97 (d, J = 4.2 Hz, 1H*0.5), 4.28-4.40 (m, 2H*0.5), 5.06 (d, J = 4.2 Hz, 1H*0.5), 5.12 (d, J = 4.5 Hz, 1H*0.5), 6.98-7.20 (m, 2H), 7.29-7.47 (m, 4H); ^{13}C NMR ($CDCl_3$, 75 MHz) δ 20.80, 20.82, 32.40, 32.54, 37.71, 37.76, 41.30, 41.71, 51.82 (2C), 69.19, 69.21, 123.46, 123.61, 125.34 (2C), 126.76, 127.04, 127.81, 127.85, 128.39, 128.41, 129.37, 129.44, 130.05, 130.22, 133.16, 133.26, 133.70, 133.99, 134.18, 134.30, 138.47, 138.52, 138.71, 138.73, 172.00, 172.16, 176.35, 176.66; ESIMS m/z 360 (M^+ +Na). Anal. Calcd For $C_{20}H_{19}NO_4$: C, 71.20; H, 5.68; N, 4.15. Found: C, 71.55; H, 5.62; N, 4.01.

Compound 7c (1:1 mixture of rotamers): 58%; orange solid, mp 154 - 156 °C; IR (KBr) 1732, 1618, 1597, 1482, 764, 752 cm^{-1} ; 1H NMR ($CDCl_3$, 300 MHz) δ 2.35 (s, 3H*0.5), 2.36 (s, 3H*0.5), 2.97-3.41 (m, 8H*0.5), 3.74 (s, 3H*0.5), 3.75 (s, 3H*0.5), 4.37-4.44 (m, 2H*0.5), 7.08-7.46 (m, 12H*0.5); ^{13}C NMR ($CDCl_3$, 75 MHz) δ 20.44 (2C), 31.93, 32.46, 37.73, 39.29, 41.56, 43.70, 51.90, 52.44, 117.73, 117.81, 124.98, 125.03, 125.07, 125.14, 127.77, 128.02, 129.11, 129.25, 129.29, 129.61,

129.85, 130.02, 133.80, 133.92, 134.05, 135.95, 137.11, 137.24, 142.55, 142.96, 145.91, 146.29, 158.23, 158.33, 171.63, 172.95, 183.15, 183.41; ESIMS m/z 358 (M^+ +Na). Anal. Calcd For $C_{20}H_{17}NO_4$: C, 71.63; H, 5.11; N, 4.18. Found: C, 71.46; H, 5.46; N, 3.97.

Acknowledgments. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0070633). Spectroscopic data was obtained from the Korea Basic Science Institute, Gwangju branch.

References and Notes

- For the synthesis and biological activities of poly-fused heterocyclic compounds having a medium-sized ring, see: (a) Bressy, C.; Alberico, D.; Lautens, M. *J. Am. Chem. Soc.* **2005**, *127*, 13148-13149. (b) Ikegashira, K.; Oka, T.; Hirashima, S.; Noji, S.; Yamanaoka, H.; Hara, Y.; Adachi, T.; Tsuruha, J.-I.; Doi, S.; Hase, Y.; Noguchi, T.; Ando, I.; Ogura, N.; Ikeda, S.; Hashimoto, H. *J. Med. Chem.* **2006**, *49*, 6950-6953. (c) Appukkuttan, P.; Dehaen, W.; der Eycken, E. V. *Org. Lett.* **2005**, *7*, 2723-2726. (d) Basavaiah, D.; Aravindu, K. *Org. Lett.* **2007**, *9*, 2453-2456.
- For the indole moiety-containing poly-fused compounds as inhibitors of hepatitis C virus (HCV) replication, see: (a) Stansfield, I.; Ercolani, C.; Mackay, A.; Conte, I.; Pompei, M.; Koch, U.; Genari, N.; Giuliano, C.; Rowley, M.; Narjes, F. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 627-632. (b) Hebermann, J.; Capito, E.; Rico Ferreira, Maria, D. R.; Koch, U.; Narjes, F. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 633-638. (c) Hirashima, S.; Oka, T.; Ikegashira, K.; Noji, S.; Yamanaoka, H.; Hara, Y.; Goto, H.; Mizojiri, R.; Niwa, Y.; Noguchi, T.; Ando, I.; Ikeda, S.; Hashimoto, H. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 3181-3186. (d) Hudyma, T. W.; Zheng, X.; He, F.; Ding, M.; Bergstrom, C. P.; Hewawasam, P.; Martin, S. W.; Gentles, R. G. *Chem. Abstr.* **2007**, *147*, 277782.
- For the Pd-catalyzed synthesis of poly-fused cyclic compounds, see: (a) Avila-Zarraga, J. G.; Lujan-Montelongo, A.; Covarrubias-Zuniga, A.; Romero-Ortega, M. *Tetrahedron Lett.* **2006**, *47*, 7987-7989. (b) Soderberg, B. C. G.; Hubbard, J. W.; Rector, S. R.; O'Neil, S. N. *Tetrahedron* **2005**, *61*, 3637-3649. (c) Rigby, J. H.; Hughes, R. C.; Heeg, M. J. *J. Am. Chem. Soc.* **1995**, *117*, 7834-7835. (d) Routier, S.; Merour, J.-Y.; Dias, N.; Lamsiaux, A.; Bailly, C.; Lozach, O.; Meijer, L. *J. Med. Chem.* **2006**, *49*, 789-799. (e) Putey, A.; Joucla, L.; Picot, L.; Besson, T.; Joseph, B. *Tetrahedron* **2007**, *63*, 867-879.
- For our previous papers on the synthesis of poly-fused heterocyclic compounds via a Pd-catalyzed cyclization, see: (a) Lee, H. S.; Kim, S. H.; Kim, T. H.; Kim, J. N. *Tetrahedron Lett.* **2008**, *49*, 1773-1776. (b) Lee, H. S.; Kim, S. H.; Gowrisankar, S.; Kim, J. N. *Tetrahedron* **2008**, *64*, 7183-7190. For the review on Pd-catalyzed reactions of Baylis-Hillman adducts, see: (c) Gowrisankar, S.; Lee, H. S.; Kim, S. H.; Lee, K. Y.; Kim, J. N. *Tetrahedron* **2009**, *65*, 8769-8780.
- For the synthesis and biological activities of 3-hydroxyoxindole moiety-containing compounds, see: (a) Nakamura, S.; Hara, N.; Nakashima, H.; Kubo, K.; Shibata, N.; Toru, T. *Chem. Eur. J.* **2008**, *14*, 8079-8081. (b) Hara, N.; Nakamura, S.; Shibata, N.; Toru, T. *Chem. Eur. J.* **2009**, *15*, 6790-6793. (c) Malkov, A. V.; Kabeshov, M. A.; Bella, M.; Kysilka, O.; Malyshev, D. A.; Pluhackova, K.; Kocovsky, P. *Org. Lett.* **2007**, *9*, 5473-5476. (d) Frechard, A.; Fabre, N.; Pean, C.; Montaut, S.; Fauvel, M.-T.; Rollin, P.; Fouraste, I. *Tetrahedron Lett.* **2001**, *42*, 9015-9017. (e) Tokunaga, T.; Hume, W. E.; Nagamine, J.; Kawamura, T.; Taiji, M.; Nagata, R. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1789-1792.

- (f) Tokunaga, T.; Hume, W. E.; Umezome, T.; Okazaki, K.; Ueki, Y.; Kumagai, K.; Hourai, S.; Nagamine, J.; Seki, H.; Taiji, M.; Noguchi, H.; Nagata, R. *J. Med. Chem.* **2001**, *44*, 4641-4649. (g) Sano, D.; Nagata, K.; Itoh, T. *Org. Lett.* **2008**, *10*, 1593-1595. (h) Inoue, M.; Takahashi, T.; Furuyama, H.; Hiramata, M. *Synlett* **2006**, 3037-3040.
6. For the reduction of isatin derivatives, see: (a) Benson, O., Jr.; Gaudiano, G.; Haltiwanger, R. C.; Koch, T. H. *J. Org. Chem.* **1988**, *53*, 3036-3045. (b) Torisawa, Y.; Nishi, T.; Minamikawa, J.-I. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 829-832. (c) Chung, Y. M.; Gong, J. H.; Kim, J. N. *Bull. Korean Chem. Soc.* **2002**, *23*, 1363-1364. (d) Chung, Y. M.; Kim, J. M.; Kim, J. N. *Bull. Korean Chem. Soc.* **2003**, *24*, 141-143.
7. For the conjugate reduction with NaBH₄, see: (a) Patra, A.; Batra, S.; Bhaduri, A. P. *Synlett* **2003**, 1611-1614. (b) Kadin, S. B. *J. Org. Chem.* **1966**, *31*, 620-622. (c) Fornasier, R.; Lucchini, V.; Scrimin, P.; Tonellato, U. *J. Org. Chem.* **1986**, *51*, 1769-1773. (d) Hayashi, Y.; Toyoshima, M.; Gotoh, H.; Ishikawa, H. *Org. Lett.* **2009**, *11*, 45-48.
8. For the air oxidation of α -hydroxy ketones, see: (a) Alamsetti, S. K.; Muthupandi, P.; Sekar, G. *Chem. Eur. J.* **2009**, *15*, 5424-5427. (b) Skobridis, K.; Theodorou, V.; Weber, E. *ARKIVOC* **2006**, 102-106. (c) Li, B.; Wang, J.; Fu, J.; Wang, J.; Zou, C. *Catal. Commun.* **2008**, *9*, 2000-2002. Later, it was found that reduction of *N*-benzylisatin **9** could be carried out in 89% with sodium dithionite (Na₂S₂O₄, 2.0 equiv) in aqueous EtOH (reflux, 1 h). The reaction medium was slightly acidic; however, compound **8** was not air-oxidized to **9** in this case. For the reduction with Na₂S₂O₄, see: (d) de Vries, J. G.; Kellogg, R. M. *J. Org. Chem.* **1980**, *45*, 4126-4129.
9. For the formation of basic species by decomposition of NaBH₄ in alcohol solvent, see: (a) Golden, J. H.; Schreier, C.; Singaram, B.; Williamson, S. M. *Inorg. Chem.* **1992**, *31*, 1533-1535. (b) Kadlec, V.; Hanzlik, J. *Collect. Czech. Chem. Commun.* **1974**, *39*, 3200-3208. (c) Busby, D. C.; George, T. A. *Inorg. Chim. Acta* **1978**, *29*, L273-L274.
-